Charles River Laboratories

Update in progress

CRL (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing worldwide. Its Research Models and Services segment sells rodents and purpose-bred models, and offers engineered models, insourcing, diagnostic services, and cell-therapy development. Discovery and Safety Assessment delivers in vitro and in vivo discovery, toxicology, pharmacokinetics, pathology, and related safety services. Manufacturing Solutions covers QC testing, biologics testing, and contract development/manufacturing. The company partners with Parker Institute for Cancer Immunotherapy, Children’s Hospital Los Angeles, and the Francis Crick Institute on ADCs. Founded 1947, HQ in Wilmington, Massachusetts.

Company score

Sentiment: -0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.44; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.59; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.42; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.42; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.38; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive